Fibrillary glomerulopathy Medical Services in China

Fibrillary glomerulopathy (FG) is a rare, progressive kidney disease characterized by the deposition of non-amyloid, randomly oriented fibrils (10–30 nm in diameter) within the glomerular basement membrane and mesangium. These fibrils are composed primarily of immunoglobulin G (IgG), often with kappa light chain predominance, and lack the beta-pleated sheet conformation seen in amyloidosis—distinguishing FG from amyloid nephropathy both histologically and biochemically. Pathogenesis remains incompletely understood but is thought to involve dysregulated immune responses, abnormal IgG folding or post-translational modification, and chronic antigenic stimulation; autoimmunity and monoclonal gammopathy are frequently associated, though most cases are idiopathic. Electron microscopy is essential for definitive diagnosis, as light and immunofluorescence microscopy may show nonspecific findings such as mesangial expansion, capillary wall thickening, and granular IgG/C3 deposits. Clinically, FG typically presents in adults aged 50–70 years, with insidious onset of proteinuria (often nephrotic-range), microscopic hematuria, hypertension, and gradually declining estimated glomerular filtration rate (eGFR). Approximately 30–40% of patients progress to end-stage kidney disease (ESKD) within 5–10 years of diagnosis without intervention. Epidemiologically, FG accounts for <1% of native kidney biopsies in large referral centers and is significantly rarer than other primary glomerulopathies like membranous nephropathy or IgA nephropathy. No clear gender predilection exists, though some cohort studies suggest a slight male predominance. Known risk factors include chronic hepatitis C infection (in a subset), autoimmune disorders (e.g., Sjögren’s syndrome, rheumatoid arthritis), and monoclonal gammopathy of undetermined significance (MGUS); however, over 60% of cases have no identifiable systemic association. Quality of life is substantially impacted: persistent edema, fatigue, recurrent infections due to hypoalbuminemia and immunosuppression, thromboembolic events, and anxiety surrounding unpredictable renal decline contribute to physical disability, work impairment, and psychosocial burden. Patients often require long-term monitoring, dietary restrictions (low-sodium, moderate-protein), diuretic therapy, anticoagulation, and eventual consideration of renal replacement therapy. The absence of standardized treatment guidelines further complicates care coordination and patient empowerment.

Fibrillary glomerulopathy (FG) is a rare, progressive immune-mediated kidney disease characterized by the deposition of non-amyloid, randomly oriented fibrils (12–24 nm in diameter) within the glomerular basement membrane and mesangium. It predominantly affects adults aged 50–70 years and often presents with nephrotic-range proteinuria, hypertension, microscopic hematuria, and gradual decline in glomerular filtration rate (GFR). Approximately 30–50% of patients progress to end-stage kidney disease (ESKD) within 5–10 years of diagnosis. Given its rarity and heterogeneous clinical course, management requires individualized, multidisciplinary care coordinated by nephrologists. No universally effective disease-modifying therapy has been established; therefore, treatment strategies integrate conservative measures, immunomodulatory pharmacotherapy, and supportive interventions—with surgical options reserved for complications or ESKD.

Conservative treatment forms the cornerstone of FG management and aims to slow disease progression, mitigate cardiovascular risk, and preserve residual renal function. Strict blood pressure control—targeting <130/80 mmHg—is essential and achieved primarily with angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor blockers (ARBs), which reduce intraglomerular pressure and proteinuria independent of antihypertensive effect. Dietary sodium restriction (<2 g/day) enhances the antiproteinuric efficacy of RAS blockade. A low-protein diet (0.8 g/kg/day) may be considered in patients with established chronic kidney disease (CKD) stages 3–4, though evidence specific to FG remains limited. Lipid management per KDIGO guidelines—including high-intensity statins—is recommended due to heightened atherosclerotic risk in nephrotic syndrome. Edema is managed with loop diuretics (e.g., furosemide or torsemide), titrated carefully to avoid intravascular depletion and acute kidney injury. Thromboprophylaxis with low-molecular-weight heparin or warfarin should be considered in patients with serum albumin <2.5 g/dL and additional risk factors for venous thromboembolism. Regular monitoring of serum creatinine, electrolytes, urinary protein-to-creatinine ratio (UPCR), and estimated GFR every 1–3 months is critical to assess trajectory and adjust therapy.

Pharmacologic intervention targets presumed autoimmune pathogenesis. While no randomized controlled trials exist for FG, retrospective cohort studies and case series inform current practice. Corticosteroids alone demonstrate minimal efficacy and are not recommended as monotherapy. The most widely adopted regimen combines corticosteroids (e.g., prednisone 0.5–1 mg/kg/day tapered over 6 months) with cyclophosphamide (oral or IV, cumulative dose ≤ 30 g) or mycophenolate mofetil (MMF) (750–1000 mg twice daily). Rituximab (375 mg/m² weekly × 4 doses or 1000 mg × 2 doses spaced 2 weeks apart) has emerged as a preferred alternative, particularly in patients intolerant to alkylating agents, given its favorable safety profile and growing evidence of sustained remission in ~40–50% of treated cases. Emerging data suggest potential benefit from bortezomib-based regimens in refractory cases, although this remains investigational. Importantly, treatment decisions must weigh risks—including infection, cytopenias, gonadal toxicity, and malignancy—against uncertain benefit. Therapy is typically initiated in patients with rapidly declining GFR (>3 mL/min/1.73 m²/year), persistent nephrotic syndrome despite maximal conservative care, or biopsy-proven active crescentic or proliferative lesions.

Surgical treatment plays no role in the direct management of FG pathology. However, kidney transplantation is the definitive therapeutic option for patients who reach ESKD. Graft survival rates are comparable to those for other primary glomerulopathies, with 5-year graft survival exceeding 85% in experienced centers. Recurrence of FG in the allograft occurs in approximately 10–20% of recipients, typically within 2–5 years post-transplant, and may lead to graft loss. Preemptive rituximab or maintenance MMF has been explored anecdotally to reduce recurrence risk but lacks robust evidence. Nephrectomy is not indicated for FG unless required for uncontrolled hypertension or recurrent infection in native kidneys—neither of which is characteristic of the disease.

China offers distinct advantages in the comprehensive management of FG. First, large tertiary hospitals—such as Peking University First Hospital, Shanghai Renji Hospital, and West China Hospital—maintain centralized rare kidney disease registries integrated with genomic and ultrastructural databases, facilitating rapid diagnostic confirmation via electron microscopy and immunofluorescence. Second, China’s national reimbursement policy covers rituximab, cyclophosphamide, and MMF under the Basic Medical Insurance scheme, significantly reducing out-of-pocket costs compared with many Western countries. Third, standardized protocols for serial kidney biopsies, digital pathology review, and longitudinal biomarker tracking (e.g., serum soluble urokinase plasminogen activator receptor [suPAR] and anti-PLA2R antibody screening to exclude mimics) enhance diagnostic accuracy and therapeutic monitoring. Fourth, China’s robust clinical trial infrastructure enables early access to novel agents—including anti-CD38 monoclonal antibodies and complement inhibitors—through investigator-initiated and multinational phase II studies. Finally, integrated traditional Chinese medicine (TCM) adjuncts—such as Huangkui capsule (a standardized extract of Abelmoschus manihot)—are supported by randomized trials demonstrating additive antiproteinuric effects when combined with RAS blockade, with favorable safety profiles validated in multicenter nephrology cohorts.

Recovery and long-term prognosis hinge on early diagnosis, consistent adherence to therapy, and proactive complication surveillance. Patients should undergo annual dual-energy X-ray absorptiometry (DEXA) scans to screen for glucocorticoid-induced osteoporosis and receive calcium/vitamin D supplementation and bisphosphonates if indicated. Vaccination against pneumococcus, influenza, hepatitis B, and SARS-CoV-2 is mandatory prior to immunosuppression. Lifestyle counseling—including smoking cessation, moderate aerobic exercise (150 min/week), and plant-dominant, low-processed-food diets—supports endothelial health and reduces systemic inflammation. Psychosocial support is integral: depression and anxiety affect >30% of CKD patients, and structured programs incorporating cognitive behavioral therapy and peer mentoring improve medication adherence and quality of life. Serial assessment of tubular biomarkers (e.g., urinary NGAL, KIM-1) and diffusion-weighted MRI may soon enable earlier detection of subclinical progression. Ultimately, while FG remains incurable, a proactive, evidence-informed, and patient-centered approach—leveraging global best practices and region-specific resources—can meaningfully delay ESKD, optimize transplant candidacy, and sustain functional independence for years.